Alto Neuroscience, Inc. (ANRO)

Market Cap	82.84M
Revenue (ttm)	n/a
Net Income (ttm)	-63.18M
Shares Out	27.07M
EPS (ttm)	-2.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,227
Open	3.030
Previous Close	3.070
Day's Range	2.970 - 3.140
52-Week Range	1.600 - 15.650
Beta	n/a
Analysts	Strong Buy
Price Target	10.40 (+239.87%)
Earnings Date	Aug 12, 2025

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 2, 2024
• Employees: 76
• Stock Exchange: NYSE
• Ticker Symbol: ANRO
• Website: https://www.altoneuroscience.com

Analyst Summary

According to 5 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price target is $10.4, which is an increase of 239.87% from the latest price.

Price Target

$10.4

(239.87% upside)

Analyst Consensus: Strong Buy